258 related articles for article (PubMed ID: 25274978)
1. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
Joura EA; Ault KA; Bosch FX; Brown D; Cuzick J; Ferris D; Garland SM; Giuliano AR; Hernandez-Avila M; Huh W; Iversen OE; Kjaer SK; Luna J; Miller D; Monsonego J; Munoz N; Myers E; Paavonen J; Pitisuttithum P; Steben M; Wheeler CM; Perez G; Saah A; Luxembourg A; Sings HL; Velicer C
Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1997-2008. PubMed ID: 25274978
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
4. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
[TBL] [Abstract][Full Text] [Related]
5. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.
Insinga RP; Perez G; Wheeler CM; Koutsky LA; Garland SM; Leodolter S; Joura EA; Ferris DG; Steben M; Hernandez-Avila M; Brown DR; Elbasha E; Muñoz N; Paavonen J; Haupt RM;
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):287-96. PubMed ID: 21300618
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.
Castellsagué X; Ault KA; Bosch FX; Brown D; Cuzick J; Ferris DG; Joura EA; Garland SM; Giuliano AR; Hernandez-Avila M; Huh W; Iversen OE; Kjaer SK; Luna J; Monsonego J; Muñoz N; Myers E; Paavonen J; Pitisuttihum P; Steben M; Wheeler CM; Perez G; Saah A; Luxembourg A; Sings HL; Velicer C
Papillomavirus Res; 2016 Dec; 2():61-69. PubMed ID: 29074187
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
[TBL] [Abstract][Full Text] [Related]
9. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
[TBL] [Abstract][Full Text] [Related]
11. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
Pérez-Castro S; Lorenzo-Mahía Y; Iñarrea Fernández A; Lamas-González MJ; Sarán-Díez MT; Rubio-Alarcón J; Reboredo-Reboredo MC; Mosteiro-Lobato S; López-Miragaya I; Torres-Piñón J; Melón-García S
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):479-85. PubMed ID: 24274937
[TBL] [Abstract][Full Text] [Related]
12. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
Ault KA; Joura EA; Kjaer SK; Iversen OE; Wheeler CM; Perez G; Brown DR; Koutsky LA; Garland SM; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Majewski S; Muñoz N; Sings HL; Harkins K; Rutkowski MA; Haupt RM; Garner EI;
Int J Cancer; 2011 Mar; 128(6):1344-53. PubMed ID: 20949623
[TBL] [Abstract][Full Text] [Related]
14. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.
Hariri S; Unger ER; Schafer S; Niccolai LM; Park IU; Bloch KC; Bennett NM; Steinau M; Johnson ML; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):393-9. PubMed ID: 25416715
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and genotype distribution of human papillomavirus in women with cervical cancer or cervical intraepithelial neoplasia in Henan province, central China.
Chen G; Zheng P; Gao L; Zhao J; Wang Y; Qin W
J Med Virol; 2020 Dec; 92(12):3743-3749. PubMed ID: 31930525
[TBL] [Abstract][Full Text] [Related]
16. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China.
Chan PK; Cheung TH; Li WH; Yu MY; Chan MY; Yim SF; Ho WC; Yeung AC; Ho KM; Ng HK
Int J Cancer; 2012 Aug; 131(3):692-705. PubMed ID: 21976212
[TBL] [Abstract][Full Text] [Related]
17. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.
Coutlée F; Ratnam S; Ramanakumar AV; Insinga RR; Bentley J; Escott N; Ghatage P; Koushik A; Ferenczy A; Franco EL
J Med Virol; 2011 Jun; 83(6):1034-41. PubMed ID: 21503917
[TBL] [Abstract][Full Text] [Related]
18. Identification of vaccine human papillomavirus genotypes in squamous intraepithelial lesions (CIN2-3).
González-Bosquet E; Esteva C; Muñoz-Almagro C; Ferrer P; Pérez M; Lailla JM
Gynecol Oncol; 2008 Oct; 111(1):9-12. PubMed ID: 18684497
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: genotype-specific prevalence and attribution.
Zhang L; Bi Q; Deng H; Xu J; Chen J; Zhang M; Mu X
BMC Infect Dis; 2017 Jan; 17(1):107. PubMed ID: 28143439
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.
Onuki M; Matsumoto K; Iwata T; Yamamoto K; Aoki Y; Maenohara S; Tsuda N; Kamiura S; Takehara K; Horie K; Tasaka N; Yahata H; Takei Y; Aoki Y; Kato H; Motohara T; Nakamura K; Ishikawa M; Kato T; Yoshida H; Matsumura N; Nakai H; Shigeta S; Takahashi F; Noda K; Yaegashi N; Yoshikawa H
Cancer Sci; 2020 Jul; 111(7):2546-2557. PubMed ID: 32372453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
